Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESPRNASDAQ:KODNASDAQ:PROKNASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$1.17+1.8%$0.99$0.69▼$3.94$232.09M0.74.83 million shs2.32 million shsKODKodiak Sciences$3.96+3.4%$3.85$1.92▼$11.60$208.93M2.28346,421 shs311,539 shsPROKProKidney$0.69+19.1%$0.77$0.46▼$2.59$201.67M1.26702,060 shs1.54 million shsRENBRenovaro$0.28-0.5%$0.32$0.27▼$2.10$47.85M0.511.57 million shs622,484 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics0.00%+17.85%-4.02%-2.42%-52.20%KODKodiak Sciences0.00%+7.03%-6.16%+81.65%+68.51%PROKProKidney0.00%+3.04%-29.52%+16.37%-69.38%RENBRenovaro0.00%-5.02%-10.00%-35.94%-82.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESPREsperion Therapeutics4.2201 of 5 stars3.43.00.03.92.61.70.6KODKodiak Sciences4.1337 of 5 stars3.04.00.04.61.13.30.0PROKProKidney1.7933 of 5 stars3.00.00.00.01.14.20.6RENBRenovaro1.1238 of 5 stars0.02.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESPREsperion Therapeutics 2.80Moderate Buy$7.00497.78% UpsideKODKodiak Sciences 2.00Hold$9.00127.27% UpsidePROKProKidney 2.00Hold$3.50407.98% UpsideRENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RENB, ESPR, PROK, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.006/17/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/7/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.004/25/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/25/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/17/2025ESPREsperion TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.004/8/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESPREsperion Therapeutics$332.31M0.70$0.02 per share48.70($1.97) per share-0.59KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/APROKProKidney$80K2,520.88N/AN/A($3.41) per share-0.20RENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESPREsperion Therapeutics-$51.74M-$0.80N/AN/AN/A-59.03%-0.91%-29.47%8/11/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)RENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%N/ALatest RENB, ESPR, PROK, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/6/2025Q1 2025ESPREsperion Therapeutics-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESPREsperion TherapeuticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESPREsperion TherapeuticsN/A1.180.81KODKodiak SciencesN/A4.624.62PROKProKidneyN/A10.9610.96RENBRenovaroN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESPREsperion Therapeutics47.39%KODKodiak Sciences89.06%PROKProKidney51.59%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipESPREsperion Therapeutics1.70%KODKodiak Sciences45.90%PROKProKidney41.49%RENBRenovaro21.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESPREsperion Therapeutics200198.20 million194.83 millionOptionableKODKodiak Sciences9052.76 million28.55 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableRENBRenovaro20172.12 million134.74 millionOptionableRENB, ESPR, PROK, and KOD HeadlinesRecent News About These CompaniesRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - NasdaqJuly 2, 2025 | nasdaq.comRenovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deRenovaro (NASDAQ:RENB) Stock Price Down 1.3% - Here's WhyJuly 1, 2025 | americanbankingnews.comRenovaro (NASDAQ:RENB) Shares Down 1.3% - Time to Sell?July 1, 2025 | marketbeat.comRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security NeedsJune 30, 2025 | accessnewswire.comARenovaro subsidiary secures patent for drug discovery AIJune 5, 2025 | uk.investing.comRENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingenJune 5, 2025 | nl.investing.comRENB stock touches 52-week low at $0.27 amid market challengesJune 5, 2025 | investing.comRenovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and DiagnosticsJune 5, 2025 | msn.comRenovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkelingJune 3, 2025 | nl.investing.comRenovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics PlatformJune 3, 2025 | globenewswire.comRenovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger AgreementMay 24, 2025 | nasdaq.comRenovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology MergerMay 22, 2025 | insidermonkey.comUPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyMay 22, 2025 | globenewswire.comRenovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyMay 22, 2025 | globenewswire.comRenovaro partners with Amsterdam UMC on cancer diagnosticsMay 15, 2025 | uk.investing.comRenovaro lanceert AI-platform voor versnelling neurologische medicijnontwikkelingMay 15, 2025 | nl.investing.comRenovaro Inc. and Amsterdam UMC Enter Exclusive Collaboration to Develop Blood Platelet RNA DiagnosticsMay 15, 2025 | nasdaq.comRenovaro launches AI platform to advance neurology drug discoveryMay 15, 2025 | investing.comRenovaro Launches Augusta, an AI-Powered Precision Neurology PlatformMay 14, 2025 | globenewswire.comRenovaro gaat samenwerking aan met Amsterdam UMC voor kankerdiagnostiekMay 13, 2025 | nl.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRENB, ESPR, PROK, and KOD Company DescriptionsEsperion Therapeutics NASDAQ:ESPR$1.17 +0.02 (+1.83%) Closing price 07/3/2025 03:42 PM EasternExtended Trading$1.16 -0.01 (-0.51%) As of 07/3/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Kodiak Sciences NASDAQ:KOD$3.96 +0.13 (+3.39%) Closing price 07/3/2025 03:35 PM EasternExtended Trading$3.89 -0.07 (-1.87%) As of 07/3/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.ProKidney NASDAQ:PROK$0.69 +0.11 (+19.06%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$0.69 0.00 (-0.44%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Renovaro NASDAQ:RENB$0.28 0.00 (-0.47%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$0.29 +0.01 (+3.96%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.